Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Abrocitinib API

Research Abrocitinib API through FDA DMF and China CDE records. Compare reported companies, interpret registration status and check chemical identity before preparing a sourcing or dossier review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

This Abrocitinib profile uses the free-base reference identity, CAS 1622902-68-4. Records are selected by reported substance name; neither source supplies a CAS field to verify the chemical form of every filing. Registry inclusion does not establish supplier qualification or current availability.

Abrocitinib registration data overview

Abrocitinib registry coverage: FDA API DMF entries (4) and CDE API registrations (1), selected by substance name. Browse free samples, then subscribe to search, filter and export the complete available records.

0 documented company-name correspondences

The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording. No cross-registry company-name correspondences are documented for this profile.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

Abrocitinib coverage: FDA DMF records (4) and CDE registrations (1). Free CSV samples contain the preview rows; a subscription opens the complete available records.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.

Reported companies in Abrocitinib registry records

Use the Abrocitinib registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.

Free previewShowing 0 sample records of 0.

0 company-name correspondences

No exact company-name correspondences are documented for these snapshots.

Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.

Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.

US REGULATORY RECORDS

Abrocitinib FDA Drug Master Files

Inspect Abrocitinib DMF holders, reported subjects, initial submission dates and activity codes. Compare the original fields before requesting dossier access. An active filing does not establish a qualified manufacturing site or an available batch.

API DMF records: 4. Distinct reported holder names: 4.

4Active (A)

0Inactive (I)

A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.

Free previewShowing 3 sample records of 4.

  • MOEHS IBERICA SLDMF number 38879Active (A)Record details
    DMF number
    38879
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2023-09-15
    Reported holder
    MOEHS IBERICA SL
    Reported subject
    ABROCITINIB
  • CHANGZHOU PHARMACEUTICAL FACTORYDMF number 39291Active (A)Record details
    DMF number
    39291
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2023-12-27
    Reported holder
    CHANGZHOU PHARMACEUTICAL FACTORY
    Reported subject
    ABROCITINIB
  • MAITHRI DRUGS PRIVATE LTDDMF number 41402Active (A)Record details
    DMF number
    41402
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2025-02-28
    Reported holder
    MAITHRI DRUGS PRIVATE LTD
    Reported subject
    ABROCITINIB

Free preview

More records available with a subscription: 1.

Inclusion criteria
  • Selected Abrocitinib Type II records: 4. Subjects match ABROCITINIB after trimming leading and trailing whitespace for selection only. Original subjects are retained, including the trailing space in DMF 39291.
  • Type II also covers intermediates and drug products, so selection requires the substance name as well as the category. No additional Abrocitinib-named subjects were found in the supplied workbook. An unqualified name does not independently verify CAS 1622902-68-4 or the chemical form of each filing.
  • All six source fields and original row order are retained. Only Excel submission dates are converted to ISO format. Activity status reflects the June 30, 2026 cutoff, not a live lookup.

CHINA REGULATORY RECORDS

Abrocitinib NMPA CDE registrations

Inspect Abrocitinib registration numbers, original Chinese company names, packaging and review status. Expand a record to read all eleven source columns, including the reported validity date and fields left blank by the source.

Name-selected API registration records: 1

1Approved or qualifying prior approval (A)

0Technical review not passed or unlinked (I)

CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.

Free previewShowing 1 sample records of 1.

  • 南通常佑药业科技有限公司Registration number Y20240000281Approved or qualifying prior approval (A)Record details
    Registration number
    Y20240000281
    Reported substance name
    阿布昔替尼
    Reported company names
    南通常佑药业科技有限公司
    Reported company addresses
    南通市如东县沿海经济开发区通海四路2号
    Reported product origin
    Domestic production (境内生产)
    Reported packaging
    15kg/桶,10kg/桶,5kg/桶,2kg/桶,1kg/桶
    Reported specification
    Not provided by source
    Record updated
    2025-08-13
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2030-08-12
    Source remarks
    Not provided by source
Inclusion criteria
  • Selected registrations named exactly 阿布昔替尼: 1. These entries are associated with this Abrocitinib reference profile. The CSV has no CAS or dedicated chemical-form field; its name alone cannot independently verify CAS 1622902-68-4 for an individual registration.
  • All eleven source columns, original row order and reported company fields are retained. No cross-registry legal-entity or manufacturing-site match is inferred from English and Chinese names.
  • Blank fields remain blank and display as Not provided by source. Packaging, dates and review codes describe the October 5, 2026 snapshot; no missing specification or current supply status is inferred.

Abrocitinib chemical identity

Abrocitinib, also known as PF-04965842, is identified here by free-base CAS 1622902-68-4 and UNII 73SM5SF3OR. The FDA-hosted CIBINQO label describes the free base as the active ingredient in the finished tablets. Abrocitinib API is the drug substance, while CIBINQO is a formulated medicine. The reference identity defines this profile; a registry name alone does not establish the composition, solid-state form or specification of an individual material.

CAS number
1622902-68-4
FDA: Abrocitinib substance identity

Free-base reference identity; the CAS of each individual filing has not been independently verified.

Abrocitinib chemical properties

The Abrocitinib formula and molecular weight below describe the free-base reference molecule. For a material comparison, request the stated chemical form, assay basis, impurity specification and batch documentation from the relevant manufacturer. Packaging recorded in a registry describes reported pack sizes; it does not establish minimum order quantities or available stock.

Molecular weight
323.42 g/mol
FDA: CIBINQO prescribing information

Chemical identity and regulatory resources

Use these official references to check Abrocitinib identifiers, distinguish the API from finished tablets and interpret the two registries.

Abrocitinib API sourcing questions

What is the Abrocitinib API identity used on this page?

This Abrocitinib profile uses free-base CAS 1622902-68-4, formula C14H21N5O2S, molecular weight 323.42 g/mol and UNII 73SM5SF3OR. These are reference identifiers for the page. The FDA and CDE records are selected by substance name and do not individually supply CAS confirmation.

Are PF-04965842, Abrocitinib and CIBINQO interchangeable names?

PF-04965842 is a reported synonym for Abrocitinib in the FDA substance record. CIBINQO is a finished-tablet medicine containing the free-base active ingredient together with excipients. A request for bulk API should specify the substance, chemical form and intended specification rather than treating the finished medicine as a raw-material product.

Which Abrocitinib FDA DMF records are included?

The supplied Q2 2026 workbook yields 4 Type II records with subjects matching ABROCITINIB after trimming whitespace for selection. Original subject text remains intact. Type II also covers intermediates and drug products, so category alone is insufficient to identify an API filing. These entries reflect the workbook cutoff rather than a live search.

Does an active Abrocitinib DMF mean FDA approval?

No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. An Abrocitinib listing does not establish supplier qualification, manufacturing-site approval, permission to reference the dossier or current availability. Verify the official record and obtain the documentation relevant to your application.

How are China CDE Abrocitinib registrations selected?

Number of registrations named exactly 阿布昔替尼 in the supplied export: 1. Abrocitinib records retain all eleven source fields, including the reported enterprise name, packaging, validity date and blank specification. The export provides no CAS field. A packaging size is a reported registry value, not an offer, minimum order or stock confirmation.

What do the CDE A and I codes mean?

For Abrocitinib registrations, CDE codes describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. Check the current official record before relying on a snapshot status or validity date.

What should I verify before sourcing Abrocitinib API?

Use the Abrocitinib records to identify reported parties and dossier references, then verify the legal entity, manufacturing site, exact chemical form, specification and right to reference the relevant dossier with the company. Request supporting batch and analytical documents for your intended use. Registry inclusion alone does not establish those points or permission to supply a destination market.

What Abrocitinib data can I view before subscribing?

The free Abrocitinib preview shows a limited sample from each registry and provides matching CSV samples. The CDE selection fits entirely within that preview. Overview counts describe the complete selected dataset. A subscription opens the remaining available records, search, status filtering and complete CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.

FDA: Abrocitinib substance identityFDA: CIBINQO prescribing informationFDA DMF list: Q2 2026 snapshotNMPA CDE API registry snapshotFDA: Types of Drug Master FilesFDA: Drug Master FilesChina API registration status explained

Data sources

Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.

FDA: Abrocitinib substance identity

Open source reference

U.S. Food and Drug Administration

Links Abrocitinib to CAS 1622902-68-4, UNII 73SM5SF3OR, molecular formula and the PF-04965842 synonym. A UNII identifies a substance and does not establish regulatory approval.

View citation evidence

“1622902-68-4”

U.S. Food and Drug Administration

Synonyms and Mappings in the FDA UNII Search Service record for ABROCITINIB.

FDA: CIBINQO prescribing information

Open source reference

U.S. Food and Drug Administration; prescribing information for Pfizer CIBINQO

Section 11 identifies the free-base active ingredient and reports its formula and molecular weight. The finished-product label does not qualify the companies listed in this profile.

View citation evidence

“tablets contain the free base of abrocitinib”

U.S. Food and Drug Administration; prescribing information for Pfizer CIBINQO

CIBINQO prescribing information, revised June 2026, section 11, printed pages 16–17.

FDA DMF list: Q2 2026 snapshot

Open source reference

U.S. Food and Drug Administration

The selected filings come from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.

View citation evidence

“ABROCITINIB”

U.S. Food and Drug Administration

Reported subject of the selected Type II records in worksheet 2Q2026-EXCEL; DMF 39291 retains its original trailing space.

FDA: Drug Master Files

Open source reference

U.S. Food and Drug Administration

Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA statement about DMFs; their technical contents are reviewed with applications that reference them.

FDA: Types of Drug Master Files

Open source reference

U.S. Food and Drug Administration

Type II is broader than APIs, so the reported subject must also be checked.

View citation evidence

“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”

U.S. Food and Drug Administration

FDA Type II category heading.

NMPA CDE API registry snapshot

Open source reference

Center for Drug Evaluation, National Medical Products Administration

The October 5, 2026 export supplies the name-selected registration, with its original Chinese company name, review code, packaging, dates and blank fields.

View citation evidence

“阿布昔替尼”

Center for Drug Evaluation, National Medical Products Administration

Exact substance name of the selected registrations in the supplied eleven-column CSV.

China API registration status explained

Open source reference

Liaoning Medical Products Administration

Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.

View citation evidence

“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”

Liaoning Medical Products Administration

Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.

Continue your Abrocitinib API research

Compare Abrocitinib registry names, review codes and chemical identity using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

Report a data issue

Report an Abrocitinib data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.

Contact data support